British pharmaceutical giant Glaxosmithkline, GSK, has entered into an agreement with Danish biotech company Muna Therapeutics, according to a press release.

Muna Therapeutics has Novo Holdings, EQT and Sanofi Ventures among its shareholders.

The agreement concerns joint research for new treatments for Alzheimer's disease. As part of this, the companies will use insights from Muna's MiND-MAP platform, which applies spatial transcriptomics to brain samples from patients with Alzheimer's disease, to identify new drug targets.

Under the terms of the agreement, GSK will provide Muna with an upfront payment of EUR 33.5 million, equivalent to SEK 385 million. In addition, Muna will be eligible to receive up to €140 million in additional payments upon the achievement of milestones, as well as royalties on sales.

This is GSK's third announced collaboration this week, after announcing one on Wednesday with DualityBio, and one yesterday with Chinese Chongqing Zhifei Biological Products.